The British pharmaceutical company GlaxoSmithKline (GSK) announced that the antibody cocktail it has prepared as an anti-coronavirus treatment in partnership with the American Vir Biotechnology is effective against the Omicron variant.
Specifically, the company announced that Sotrovimab is effective against all 37 Omicron mutations that scientists have identified.
The company cites data from an initial stage study, which has not yet been published.
The drug, which will be released under the name Xevudy, was approved for use last week by the British Regulatory Authority for Medicines and Health Products.
It has been shown to reduce the risk of hospitalization and death by 79%.